Dionisia Quiroga conducted a single-arm, open-label phase II clinical trial on the combination of a toll-like receptor 9 agonist (CpG ODN) with trastuzumab for the treatment of patients with advanced/metastatic HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.